Cyclerion Therapeutics, Inc. — Director's Dealing 2021

Mar 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclerion Therapeutics, Inc. (CYCN)
CIK: 0001755237
Period of Report: 2021-02-25

Reporting Person: Gjino Anjeza (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-25	Common Stock	S	1824	$4	Disposed	31599	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.